ABSTRACT-In the present study, we investigated the effects of MCI-727, a new anti-ulcer agent, on plasma immunoreactive secretin concentration in rats and dogs us ing secretin specific RIA with the ethanol extraction method. Plasma secretin levels were increased dose-dependently 10 min after oral administration of MCI-727 in rats (control: 5.5 ± 0.6; MCI-727, 10 mg/kg: 10.4 ± 2.6; 30 mg/kg: 15.3 ± 1.5; 100 mg/kg: 20.7 ± 2.6 pg/ml, n = 6). Teprenone also caused a significant increase of plasma secretin at 10 min after oral administration at the doses of 30, 100 and 300 mg/kg. Under the same conditions, MCI-727 and teprenone did not alter the plasma immunoreactive gastrin concentration in rats. From the results of the time course study, the increasing effect of MCI-727 (30 mg/kg, p.o.) on plasma secretin remained for at least 240 min after administration. On the other hand, the increasing effect of teprenone (200 mg/kg, p.o.) was only observed at 30 and 60 min after administration. Furthermore, MCI-727 had increasing effects on plasma secretin concentration in dogs, but teprenone had no effects in this species. The volume of pancreatic secretion and the pancreatic bicarbonate output increased after intra-duodenal administration of MCI-727 at 30 and 100 mg/kg in rats. Similar effects were also observed with tepre none (30 300 mg/kg, i.d.) or secretin (Secrepan R', 0
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MCI-727 ((Z)-2-(4-methylpiperazin-1-yl)-1-[4 (2-phenyl-ethyl)phenyl]-ethanone oxime hydro chloride monohydrate) is an anti-ulcer agent with a new chemical structure, and it has more potent anti-ulcer effects than cimetidine or teprenone in various experimental ulcer mod els (1) . The mechanism of the anti-ulcer effect of this agent has not been clearly defined. It has no effects on basal gastric acid secretion and histamine or 2-deoxyglucose-stimulated gastric acid secretion, but suppressed the tetragastrin-stimulated one. Since a similar pattern of action has been reported with secre tin (2-4), one of the gut peptides (5) which has anti-ulcer activity (6), the participation of endogeneous secretin in the anti-ulcer mechanism of this agent was suggested. There fore, in the present study, we investigated the effects of MCI-727 on plasma secretin concen tration in rats and dogs. The effects on plasma gastrin concentration and pancreatic exocrine secretion in rats were also investigated. Tepre none, an anti-ulcer agent which has an en hancing action on the gastric mucus and mucus and mucosal barrier (7), was employed as a reference drug in these experiments. Tepre none also has been reported to increase the plasma secretin concentration (8) . 
MATERIALS AND METHODS
In experiments 1, 2 and 4, male Donryu rats (Japan SLC) weighing 250-300 g were placed in a wire cage individually and deprived of food but allowed free access to water for 24 hr before the experiments. In experiment 3, male and female mongrel dogs weighing 8 -16 kg were used. Dogs were prepared with a chronic gastric fistula and were allowed to recover from the surgical operation for at least 2 weeks. Before the experiment, dogs were dep rived of food but allowed free access to water for 24 hr. All animals were housed in a temperature (23 ± I -C) and humidity (50 ± 5%) controlled room under a 12 hr light-dark cycle (7:00 to 19:00, light on).
MCI-727 ( Fig. 1 ) was synthesized in our laboratory. Teprenone was extracted from Sel bex capsules' (Eisai). In the experiment us ing rats, MCI-727 was suspended with 2.51-1c gum Arabic solution, and teprenone was sus pended with 0.5% Tween 80 solution. All test drugs or vehicle were given in a volume of 0.2 ml/100 g body weight. In the experiment using dogs, all test drugs were suspended in a solu tion containing 2.5% gum Arabic and 0.511c Tween 80 and administered in the volume of 10 ml/body. The pH of the drug suspensions and vehicle were adjusted to 6.0 ± 1.0 in all experiments.
Other compounds used were as follows: Ethanol, borax (sodium tetraborate), gum Arabic (powder) (Junsei Chemical Co.); Tween 80 (polyoxyethylene sorbitan monoole ate), HCI (hydrochloric acid), NaOH (sodium hydroxide), NaN3 (sodium azide), tris (tris hydroxyl methyl-amino methane), Na2HPO4 (di sodium hydrogenphosphate), NaH2PO4 (sodium dihydrogenphosphate), SMBS (sodium metabi sulfite), chloramine-T, KI (potassium iodide), sucrose (Nacalai Tesque); Sephadex G-15, Sephadex G-50, SP-Sephadex C-25 (Pharma cia); NaCI (sodium chloride) ( Ten minutes after oral administration of test drugs or vehicle, the blood was collected from the aorta into the heparin added tube and kept on ice during the test period. Blood sam pling was carried out under sodium pentobar bital (40 mg/kg, i.p.) anesthesia. Blood was centrifuged at 3000 rpm for 30 min at 4°C, and plasma was collected. For the secretin assay, a 2-ml aliquot of plasma was taken, to which 40 ,ul of aprotinin was added. For the gastrin assay, 0.5 ml of plasma was taken, to which 10 ,ul of aprotinin was added. The sample plasma was frozen at -80'C for future assay.
Plasma secretin concentration was deter mined by the radioimmunoassay methods (RIA) described by Chey et al. (9, 10) . Prior to RIA, secretin was extracted from plasma by ethanol (11) by the following procedure: Two ml of ethanol and 2 ml of plasma sample were added into the tube and mixed. After 10 min, the mixture was centrifuged at 3000 rpm for 30 min at 4'C, and then 6 ml ethanol was added and mixed; after 10 min, the mixture was con trifuged again under the same conditions. The supernatant was collected and evaporated to dryness in a stream of N2-gas. The dried re sidue was redissolved in 1 ml of standard diluents (0.05 M sodium phosphate buffer, pH 7.0, containing 0.02% NaN3 and 0.5% BSA) before the RIA. The RIA for secretin was performed as follows: secretin standard was dissolved by the standard diluent at the con centration of 1.25 -160 pg/0.2 ml/tube. Anti secretin serum R-5-6 (kindly provided by Pro fessor W.Y. Chey, University of Rochester, NY, U.S.A.) was dissolved by antiserum diluent (0.5 M sodium phosphate buffer, pH 7.0, containing 0.02% NaN3, 0.1% BSA and 300 U/ml aprotinin) (final dilution of 1 : 5,000,000). '2'I-Secretin was prepared to approximately 5000 cpm/0.2 ml/tube with the standard diluent. Iodination of secretin was prepared by the chloramine-T method (11): synthetic porcine secretin (5 u g/20 u l), Na[1251] (74 MBq), chloramine-T (25 ,ug/5,ul) and 0.5 M borax buffer, pH 8.0 (10 ,u l) were mixed and gently shaken at room tempera ture. Two minutes later, SMBS (1.25 mg/50 ,u l) and 80 ,u l of transfer solution (0.5M suc rose, 0.05M KI, 1.6% BSA and 0.02% NaN3) were added, and the reaction mixture was applied to a Sephadex G-15: Sephadex G 50 (7 : 3) column (00.9 X 19 cm high). The second peak fractions were collected and di luted and applied to a SP-Sephadex C-25 col umn at 4''C (00.9 X 19 cm high). The '251-sec retin was eluted from the column with 0.02 M sodium phosphate buffer, pH 5.5, containing 1 % BSA with a 0.02 M to 0.2 M NaCI gra dient. '251-Secretin fractions, the major radioactive peak, were collected and rechro matographed over SP-Sephadex C-25 under the same conditions. Purified '2 I-secretin was kept frozen at -20°C. All assays were set up in duplicate in 10 X 75 mm glass culture tubes at 4-"C. Secretin standard (for the standard curve tube, 0.2 ml) or standard diluent (for sample tube, 0.2 ml), hormone-free plasma ex tract (for standard curve tube, 0.4 ml) or sam ple (for sample tube, 0.4 ml) and antiserum (0.2 ml) were mixed and preincubated for 48 hr; then 1251-secretin (5000 cpm/0.2 ml) was added and incubated for 48 hr. The total in cubation volume was 1.0 ml. Plasma coated dextran charcoal (0.4 ml of a mixture consist ing of 1 part citrate-free plasma and 1 part 0.45% dextran, 4.5% charcoal, 0.02% NaN3 in 0.5 M tris-HCI buffer, pH 7.8) was added for the Bound/Free separation and incubated for 30 min, followed by centrifugation at 3000 rpm for 30 min. The supernatant fluid contain ing the antibody-bound secretin was decanted to another tube and counted by a gamma-ray counter. The minimum detected limit of secre tin concentration was 1 2 pg/ml plasma.
Plasma gastrin concentration was deter mined in duplicate by RIA with an assay kit (Gastrin RIAKITR II, Dainabot) and the limit of detection was 25 pg/ml plasma.
Experiment 2. Time course changes in plasma secretin concentration in rats
Test drugs were administered orally, and the blood was collected after 10, 30, 60, 120, 240 and 480 min. Control rats were adminis tered the vehicle at 1O min before the blood sampling. Other protocols were the same as described in experiment 1.
Experiment 3. Effects on plasma secretin con centration in dogs
Each dog was fixed in the Pavlov-stand and an intracatheter for blood sampling was in serted in a peripheral vein of one of the extre mities and maintained patent with a slow infu sion of saline solution. The gastric fistula was opened and washed the gastric lumen with wa ter. After the first blood sampling, cimetidine (10 mg/kg) was given intra-venously as a bolus to exclude the influence of gastric acid secre tion. Test drug suspension (10 ml/body) was administered from the gastric fistula at 60 min after cimetidine treatment, and the remaining suspension at the inner space of the fistula was pushed two times by 10 ml of distilled water. Blood samples were drawn from the intra catheter (5 ml/sampling) at 0, 5, 10, 15, 30, 60 and 120 min after test drug administration. Other protocols were the same as described in experiment 1.
Experiment 4. Effects on pancreatic exocrine secretion in rats
The experiment was carried out under urethane (1.2 g/kg, i.p.) anesthesia. After tracheostomy, the abdomen was opened, and the polyethylene cannula put into the duode num through the pyrolus from the small hole of the forstomach and pyrolus was ligated and the cannula was fixed. The pancreatic duct was cannulated in the duodenal wall with a polyethylene tube. The bile duct was ligated near the liver, and bile was drained out through a polyethylene tube inserted into the bile duct. The femoral vein was catheterized with a polyethylene tube. After the recovery interval (approximately I hr), the polyethylene cannula (internal volume of which was cali brated before the experiment) was attached to the pancreatic cannula in order to measure the pancreatic juice volume. After 60 min, the suspension of MCI-727 or teprenone was administered into the duodenal lumen through the duodenal cannula or the solution of Secrepan R was intra-venously administered from the femoral vein cannula. The volume of pancreatic exocrine secretion and bicarbonate output was measured for 120 min at 30 min in tervals. Bicarbonate (HCO3 ) of the pancrea tic juice was measured by a CO,-analyzer (Corning). Porcine secretin (Secrepan R) was used for the positive control.
Data analysis
Statistical analyses were performed using the paired (experiment 3) or unpaired (other experiments) Student's t-test, and values of P < 0 .05 were regarded as indicating a statisti cally significant difference. Fig. 2 . Effect of MCI-727 and teprenone on plasma secretin concentration in rats. Plasma secretin was measured 10 min after oral administration of each drug. Control rats were administered 2.5% gum Ara bic solution (MCI-727) or 0.5% Tween-80 solution (teprenone). Results are expressed as the mean ± S.F. (n = O. * P < 0.05, **P < 0.01: Significant dif ference from the control rats.
RESULTS

Experiment 1. Effects on plasma secretinn con centration in rats
The oral administration of MCI-727 at 10, 30 and 100 mg/kg increased the plasma secre tin concentration in a dose-related manner with mean values of 10.4, 15.3 and 20.5 pg/ml, respectively (Fig. 2) . The mean con centration of plasma secretin in control rats (2.5% gum Arabic solution, p.o.) was 5.5 pg/ml.
The oral administraion of teprenone 10 mg/kg had no effect, but 30, 100 and 300 mg/kg increased the plasma secretin concen tration with mean values of 15.4, 16.1 and 21.2 pg/ml, respectively. The mean concentra tion of plasma secretin in control rats (0.5% Tween 80 solution, p.o.) was 6.1 pg/ml.
The plasma gastrin concentration in 2.5%
gum Arabic solution treated rats and 0.5% Tween 80 solution treated rats were 141.0 pg/ml and 130.2 pg/ml, respectively. Follow ing administration of MCI-727 and teprenone, plasma gastrin concentration did not change significantly from the control values (Fig. 3) .
Experiment 2. Time course changes in plasma secretin concentration in rats
The plasma secretin concentration was signi ficantly increased at 10, 30, 60, 120 and 240 min after oral administration of MCI-727 (30 mg/kg) (Fig. 4, upper) . The maximal increase of secretin concentration was shown at 60 min after administration with the mean value of 12.0 pg/ml.
The oral treatment of teprenone (200 mg/kg) significantly increased plasma secretin concentration at 30 and 60 min after adminis tration, and the maximal increase was observed at 30 min with the mean value of 13.7 pg/ml (Fig. 4, lower) . (n = 9 -10). * P < 0.05, ** P < 0.01: Significant dif ference from the control rats.
Experiment 3. Effects on plasma secretin con centration in dogs
The basal plasma secretin concentration in dogs was 5 10 pg/ml, and it was not altered by cimetidine (10 mg/kg, i.v.) pretreatment. The intra-gastric administration of MCI-727 (30 mg/kg) significantly increased plasma sec retin concentration after 5 to 30 min. The maximal response was shown at 5 min with the mean value of 30.0 pg/ml (Fig. 5, upper) .
The intra-gastric administration of tepre none (200 mg/kg) caused no significant changes in the plasma secretin concentration (Fig. 5,  lower) . The plasma secretin concentration remained unaltered after intra-gastric administration of vehicle. (Fig. 6) .
The intra-duodenal treatment of teprenone (30, 100 and 300 mg/kg) significantly in creased the volume (16.1, 30.5 and 34.5 ,ul/30 min, respectively) and the HCO3 (0.67, 1.56 and 2.15 ,uEq/30 min, respectively) at 60 min after administration (Fig. 7) .
The intra-venous treatment of Secrepan'R (0.1 and 1.0 unit/kg) increased the volume (14.7 and 29.0 ,ul/30 min, respectively) and the HCO3 (0.47 and 1.66 ,uEq/30 min, re spectively) at 30 min after administration (Fig.  8) . No significant changes in the volume and HCO3 secretion were observed in the control rats. 
DISCUSSION
Based upon the results of the previous study on the effect of MCI-727 on gastric acid secre tion (1), we assumed that the endogeneous secretin may participate in part in the mecha nism of the anti-ulcer effect of this agent. In the first experiment, we determined the plas ma secretin concentration after oral adminis tration of MCI-727 in rats. MCI-727 (10, 30 and 100 mg/kg) increased the plasma secretin concentration dose-dependently (Fig. 2) . This finding indicates that MCI-727 has en dogeneous secretin releasing action. According to Shiratori et al. (12) , the infusion of secretin (0.05 CU/kg/hr) increased the plasma secretin concentration with the value of 21.6 pg/ml (basal value was 4.1 pg/ml) and inhibited the tetragastrin-stimulated gastric acid secretion in man. Chey and Konturek (13) also reported that the exogenous secretin (0.03 CU/kg/hr) treatment increased the plasma secretin con centration with the value of approximately 15 pg/ml (basal value was 6 pg/ml) and stimu lated the pancreatic exocrine secretion in dogs. These results suggest that the low level of plasma secretin can produce the physio logical action (12, 13) . In order to demonstrate the physiological action of plasma secretin induced by MCI-727, we examined the effect of MCI-727 on pan creatic exocrine secretion in rats. The volume of pancreatic exocrine secretion and pancreatic HC03 outputs were significantly increased after MCI-727 treatment (Fig. 6) . A similar effect was also observed with teprenone ( Fig.  7) and SecrepanR (Fig. 8) . Thus, the study clearly indicates that MCI-727 has en dogeneous secretin releasing activity, and the rise in secretin is sufficient to induce the physiological action. In addition to this effect, MCI-727 inhibited the gastrin-induced gastric acid secretion and depressed the gastric motil ity (1) . Corresponding effects were also observed for secretin (2 4, 13 -15) .
In the present study, we also investigated the effects of MCI-727 and teprenone on plas ma gastrin concentration in rats. The plasma gastrin level was not altered significantly by the oral administration of MCI-727 and tepre none (Fig. 3) , so it was suggested that both drugs stimulate the secretin release without in fluencing the gastrin release.
In the second experiment, the time course changes in the effects of MCI-727 (30 mg/kg) and teprenone (200 mg/kg) on plasma secretin concentration in rats were investigated. The increasing effect of MCI-727 (30 mg/kg) on plasma secretin concentration was already apparent after 10 min of oral administration and this remained for 240 min (Fig. 4, upper) . On the other hand, oral administration of tep renone (200 mg/kg) also increased the plasma secretin concentration, but the significant in creases were only observed at 30 and 60 min after administration (Fig. 4, lower) . Up to now, there have been no time course studies on plasma secretin concentration after the treatment of secretin releasing agents. How ever, with regards to plasma secretin concen tration induced by ingestion of a meal, it was reported that the increasing effect was observed until approximately 3 4 hr after the meal in man (14) . From these data, it may be suggested that the duration of action on plas ma secretin concentration of MCI-727 was long enough. Furthermore, we previously de monstrated that MCI-727 (30 mg/kg, p.o.) and teprenone (200 mg/kg, p.o.) prevented HCI-ethanol induced gastric lesion (1) with the same inhibitory potency at 30 min after admin istration, but the duration of the anti-ulcer ac tion of MCI-727 was more than 4 times longer than those of teprenone. We also observed that the administration of synthesized secretin prevented the formation of HCI-ethanol in duced gastric lesion (M. Kawamura et al., un published data). In the present study, the duration of the effect of MCI-727 on plasma secretin concentration was shown to be about 4 times longer than the case of teprenone. The potency ratio of MCI-727 to teprenone (MCI 727 : teprenone = 4 : 1) in the duration of the increasing effect on plasma secretin agreed well with that in the duration of the anti-ulcer effect (HCI-ethanol ulcer model).
We have further shown in the present study that the plasma secretin increasing effect of MCI-727 was also observed in dogs. The max imal response of MCI-727 (30 mg/kg) on plas ma secretin concentration was higher than that after teprenone (200 mg/kg), which showed no significant increases in contrast with rats (Fig. 5) . The reason for the difference is not clear at present.
The regulating factors of secretin-release are poorly understood. Release of secretin is not under parasympathetic nerve control (16, 17) , and other nerves controls are not known. The mechanisms of secretin release of the com pounds which have increasing action on plas ma secretin such as fatty acids (18, 19) , bile (20) , licorice extract (Fm 100) (21), teprenone (8) and plaunotol (22) are yet unclear. As for HCI which also increases the plasma secretin in vivo (23) , it may be suggested that secretin release was induced by the direct stimulating action on the duodenal mucosa from an in vitro study (24) . In our preliminary study, MCI-727 also stimulated secretin secretion from isolated rat duodenal mucosa in vitro, so we assumed that the increasing action of MCI 727 on plasma secretin was caused by a direct action to the duodenum.
In conclusion, we have clearly shown that MCI-727 increased the plasma secretin con centration and pancreatic secretion without in fluencing the plasma gastrin concentration.
The increasing effect on plasma secretin may play a role, in part, in the mechanisms of the anti-ulcer effects of this agent.
